Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. **(Currently Amended)** A method of modulating NF-κB induction in a cell comprising contacting a cell with an effective amount of an anti-inflammatory compound comprising at least one NF-κB Essential Modulator (NEMO) ~~NEMO~~ binding domain, thereby modulating NF-κB induction in a cell.

2. **(Currently Amended)** The method of claim 1, wherein the anti-inflammatory compound ~~is capable of blocking~~ blocks the interaction between one or more IκB protein kinases (IKKs) ~~IKKs~~ and NF-κB Essential Modulator (NEMO) ~~NEMO~~.

3. **(Currently Amended)** The method of claim 2, wherein the IκB protein kinase (IKK) ~~IKK~~ is selected from the group consisting of IKKα and IKKβ.

4. **(Original Claim)** The method of claim 1, wherein the anti-inflammatory compound further comprises at least one membrane translocation domain.

5. **(Currently Amended)** The method of claim 1, wherein the NF-κB Essential Modulator (NEMO) ~~NEMO~~ binding domain comprises the amino acid sequence set forth in SEQ ID NO:2, 4, 5, 6, 11, 12, 16 or 17.

6. **(Currently Amended)** A method for treating a subject suffering from an inflammatory disorder comprising administering to said subject an anti-inflammatory compound comprising at least one NF-κB Essential Modulator (NEMO) binding domain in an amount and for a period of time effective to block the recruitment of leukocytes into sites of inflammation, thereby treating ~~treat~~ said subject suffering from an inflammatory disorder.

7. **(Currently Amended)** The method of claim 6, wherein the anti-inflammatory compound ~~is capable of inhibiting~~ inhibits the recruitment of leukocytes into sites of ~~acute and~~ chronic inflammation.

8. **(Currently Amended)** The method of claim 6, wherein the anti-inflammatory compound ~~is capable of down-regulating~~g down-regulates the expression of E-selectin on endothelial cells.

9. **(Currently Amended)** The method of claim 6, wherein the anti-inflammatory compound ~~is capable of inhibiting~~ inhibits osteoclast differentiation.

10. **(Currently Amended)** A method of modulating NF-κB-dependent target gene expression in a cell comprising contacting a cell with an effective amount of an anti-inflammatory compound comprising at least one NF-κB Essential Modulator (NEMO) ~~NEMO~~ binding domain, thereby modulating NF-κB-dependent target gene expression in a cell.

11. **(Currently Amended)** The method of claim 10, wherein the anti-inflammatory compound ~~is capable of blocking~~ blocks the interaction between one or more IκB protein kinases (IKKs) ~~IKKs~~ and NF-κB Essential Modulator (NEMO) ~~NEMO~~.

12. **(Currently Amended)** The method of claim 11, wherein the IκB protein kinase (IKK) ~~IKKs~~ is IKKβ.

13. **(Original Claim)** The method of claim 10, wherein the NF-κB-dependent target gene is E-selectin.

14-26. **(Cancelled)**

27. **(Currently Amended)** A method of treating an NFkB-mediated condition in a subject, comprising administering to the subject ~~an effective amount of an anti-inflammatory compound which inhibits binding of NEMO to an IKK~~ an anti-inflammatory compound comprising at least one NF-κB Essential Modulator (NEMO) binding domain in an amount and for a period of time effective to inhibit the binding of NF-κB Essential Modulator (NEMO) to an IκB protein kinase (IKK), thereby treating an NFkB-mediated condition in a subject.

28. **(Original Claim)** The method of claim 27, wherein the NFkB-mediated condition is an inflammation disorder, an autoimmune disease, transplant rejection, osteoporosis, cancer, Alzheimer's disease, atherosclerosis, a viral infection, or ataxia telangiectasia.

29. **(Original Claim)** The method of claim 28, wherein the inflammation disorder is selected from the group consisting of asthma, allergies, uticaria, anaphylaxis, cutaneous

inflammation, sepsis, psoriasis, rheumatoid arthritis, osteoarthritis, psoriatic arthritis, inflammatory bowel disease, chronic obstructive pulmonary disease, vasculitis, and bursitis.

30. **(Original Claim)** The method of claim 28, wherein the inflammation disorder is selected from the group consisting of dermititis, eczema, psoriasis, osteoarthritis, psoriatic arthritis, lupus and spondylarthritis.

31. **(Cancelled)**

32. **(Currently Amended)** The method of claim 27, wherein the anti-inflammatory compound comprises at least one NF-κB Essential Modulator (NEMO) ~~a NEMO~~ binding domain and at least one membrane translocation domain.

33. **(Original Claim)** The method of claim 32, wherein the membrane translocation domain is selected from the group consisting of the third helix of the *antennapedia* homeodomain and HIV-1 Tat protein.

34. **(Currently Amended)** The method of claim 32, wherein the NF-κB Essential Modulator (NEMO) ~~NEMO~~ binding domain comprises the amino acid sequence set forth in SEQ ID NO: 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16 or 17.

35. **(Cancelled)**